Short Interest in Autonomix Medical, Inc. (NASDAQ:AMIX) Increases By 1,052.8%

Autonomix Medical, Inc. (NASDAQ:AMIX) was the recipient of a large growth in short interest during the month of December. As of December 31st, there was short interest totaling 1,543,188 shares, a growth of 1,052.8% from the December 15th total of 133,864 shares. Based on an average daily trading volume, of 12,719,755 shares, the short-interest ratio is presently 0.1 days. Approximately 23.8% of the shares of the company are short sold. Approximately 23.8% of the shares of the company are short sold. Based on an average daily trading volume, of 12,719,755 shares, the short-interest ratio is presently 0.1 days.

Autonomix Medical Stock Performance

Shares of AMIX opened at $0.50 on Wednesday. The firm has a market cap of $3.46 million, a price-to-earnings ratio of -0.11 and a beta of -2.59. Autonomix Medical has a fifty-two week low of $0.47 and a fifty-two week high of $3.33. The firm has a 50 day moving average price of $0.75 and a 200-day moving average price of $1.05.

Autonomix Medical (NASDAQ:AMIX) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($1.38) EPS for the quarter, hitting analysts’ consensus estimates of ($1.38). As a group, equities research analysts predict that Autonomix Medical will post -10 earnings per share for the current year.

Wall Street Analyst Weigh In

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Autonomix Medical in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $5.00.

Autonomix Medical Company Profile

Autonomix Medical, Inc, a development stage medical device development company, focuses on advancing technologies for sensing and treating disorders relating to the peripheral nervous system. Its technology platform includes a catheter-based microchip-enabled sensing array to detect and differentiate peripheral neural signals. The company was incorporated in 2014 and is based in The Woodlands, Texas.